FELIQS Series A Funding and FLQ-101 Clinical Program FAQ

What is FELIQS Corporation?

FELIQS is a biotechnology company based in Fukuoka, Japan, focused on developing first-in-class small molecule therapeutics for rare pediatric retinal diseases, with its lead program targeting retinopathy of prematurity.

What is FLQ-101?

FLQ-101 is FELIQS’s lead candidate, a once-daily oral or intravenous solution designed to enhance physiological retinal vascularization and protect against inflammation and abnormal neovascularization in premature infants.

Why is the Series A funding significant for FELIQS?

The $9 million Series A funding enables FELIQS to accelerate the clinical development of FLQ-101, expand its team, and strengthen research initiatives, marking a critical milestone in addressing retinopathy of prematurity.

Who are the key investors in FELIQS’s Series A round?

The funding round was co-led by a major American pharmaceutical company and Beyond Next Ventures Inc., with participation from Japan Science and Technology Agency, Mitsubishi UFJ Capital Co., Ltd., Keio Innovation Initiative, Inc., and FFG Venture Business Partners Co., Ltd.

What are the next steps for FLQ-101’s clinical development?

FELIQS plans to commence the Phase 1b/2 tROPhy-1 study in the summer of 2025 in the United States, following the FDA’s Fast Track and Orphan Drug designations granted in 2024.

What designations has FLQ-101 received from the FDA?

FLQ-101 has been granted both Fast Track and Orphan Drug designations by the U.S. FDA, recognizing its potential to meet a significant unmet medical need in neonatal care.

How does FLQ-101 aim to benefit premature infants?

FLQ-101 is designed to prevent retinopathy of prematurity by enhancing retinal vascularization and protecting against inflammation and abnormal neovascularization, potentially preventing blindness in premature infants.

Where is FELIQS’s clinical research being advanced?

FELIQS is advancing its clinical research in the United States, with the Phase 1b/2 tROPhy-1 study scheduled to begin in the summer of 2025.

Who can be contacted for more information about FELIQS and FLQ-101?

The content does not specify contact information, but interested parties may seek more information through FELIQS Corporation’s official channels or the mentioned investors and legal counsel, Latham & Watkins.